The Global Market for CNS Therapeutics is Projected to Reach US$129 Billion by 2020

Rising Incidence of CNS Disorders & a Promising Global Drug Pipeline Drive the CNS Therapeutics Market, According to a New Report by Global Industry Analysts, Inc.

GIA announces the release of a comprehensive global report on the CNS Therapeutics. The global market for CNS Therapeutics is projected to reach US$129 billion by 2020, driven by the rapidly aging population, rising incidence of CNS disorders, and an encouraging pipeline of late stage drugs.

The global CNS therapeutics market is driven by the increasing incidence of CNS disorders, aging population, rising healthcare spending, and an encouraging pipeline of late stage drugs. The unmet medical needs for diagnosing and treating CNS conditions, brings to fore the untapped potential in the market. Presently, there exists an urgent need for developing safe and effective drugs that overcome the limitations of current generation drugs. Companies are therefore investing to develop novel drugs for neurodegenerative diseases. The industry has achieved significant success in the development of safe, effective and side effect-free therapies complemented with convenient drug administration solutions. The next big healthcare movement is forecast to occur in the field of neurology. CNS drugs, in this regard, are forecast to witness strong growth with Alzheimer's and Parkinson's diseases emerging as the two most important therapeutic categories.

Aging population and a parallel rise in the incidence of Parkinson’s and Alzheimer’s diseases is a key factor driving growth in the market. The number of people aged over 60 years currently has doubled as compared to the early 1980s and is expected to quadruple by 2050. This demographic shift will not only impact societies and economies worldwide, but will also influence the healthcare sector. Increased demand for combination therapies and growing use of generics are important trends in the market. Introduction of new Alzheimer’s drugs, including anti-amyloid proteins, cholinergic and nicotine receptor agonists, Neuro protective drugs, vaccines and GABA receptor modulators, will also help support growth in this space.

The market is also witnessing the launch of novel therapies for the treatment of Parkinson’s disease, such as adenosine and andrenergic agonists, glutamate receptor modulators, and dopamine receptor agonists. Other disease conditions fuelling an increase in CNS prescriptions include pain manifestations, psychiatric disorders (schizophrenia, sleep disorders, depression and anxiety), cerebrovascular disorders, stroke, seizures, cognitive and memory disorders. As most of the top selling branded CNS drugs begin to come off patent in the coming decade, leading players will witness their sales suffer due to generic erosion. The impact of generic erosion will however be partially offset by the development of newer, expensive premium-priced third generation drugs. Third generation AED drugs will increasingly find new therapeutic applications as adjunctive agents and will largely be used as the last line of treatment and will therefore have moderate sales and limited ability to offset generic competition at-least in the medium term. Among the third generation agents, anti-epileptogenic treatment is forecast to hold attractive potential in meeting the yet huge unmet medical needs in epilepsy.

As stated by the new market research report on CNS Therapeutics, the United States represents the largest market worldwide. Asia-Pacific ranks as the fastest growing market with a CAGR of about 3.7% over the analysis period. The market for anti-epilepsy drugs will witness the fastest growth, with revenues growing at a CAGR of about 2.9% over the analysis period.

           

Major players in the global market include AbbVie Inc., Actavis Plc., Alkermes Plc., Amneal Pharmaceuticals, LLC, Aspen Pharmacare Holdings Limited, AstraZeneca Plc, BEACON Pharmaceutical Limited, BIAL Group, Boehringer Ingelheim GmbH, Bristol-Myers Squibb, Dainippon Sumitomo Pharma Co. Ltd., Eisai Co. Ltd., Eli Lilly and Co., F. Hoffmann-La Roche Ltd., Fabre-Kramer Pharmaceuticals Inc., GlaxoSmithKline, H. Lundbeck A/S, Janssen Pharmaceuticals Inc., Johnson & Johnson, Merck & Co. Inc., Neurocrine Biosciences Inc., Novartis AG, Otsuka Pharmaceutical Co. Ltd., Pfizer Inc., Sanofi S.A, Shire Plc, Sunovion Pharmaceuticals Inc., Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., and UCB Group, among others.

The research report titled “CNS Therapeutics: A Global Strategic Business Report” announced by Global Industry Analysts Inc., provides a comprehensive review of trends, growth drivers, restraints, market share, size and demand projections and forecasts. Major geographic regions covered include the US, Canada, Japan, Europe (France, Germany, Italy, UK, Spain, Russia and Rest of Europe), Asia-Pacific (China, India, and Rest of Asia-Pacific), Latin America (Brazil and Rest of Latin America), and Rest of World. Product segments analyzed in the report include Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Others (Include Insomnia, Multiple Sclerosis, and ADHD). The report also offers coverage on mergers, acquisitions, product launches, and other strategic industry activities of major global and regional players.